April 28, 2015 Mr. Scott D. Cormack President and Chief Executive Officer OncoGenex Pharmaceuticals, Inc. 19820 North Creek Parkway, Suite 201 Bothell, WA 98021Letter Agreement • April 30th, 2015 • Oncogenex Pharmaceuticals, Inc. • In vitro & in vivo diagnostic substances • New York
This letter (this “Letter Agreement”) will confirm our agreement with OncoGenex Pharmaceuticals, Inc., a Delaware corporation (the “Company”) with respect to the engagement of Academy Securities, Inc., a Delaware corporation, and a broker-dealer registered with the U.S. Securities and Exchange Commission (“SEC”) and a member of the Financial Industry Regulatory Authority (“FINRA”) as exclusive placement agent (“Agent”) for the Company in connection with the best efforts placement of the Company’s common stock to Lincoln Park Capital Fund, LLC (the “Investor”), as more fully described herein (the “Transaction”). Agent hereby agrees, on a best efforts basis and subject to the satisfactory completion of its due diligence, to place up to $16,300,000 of the Company’s authorized but unissued common stock (the “Common Stock” or “Common Shares”) and $2,000,000 of the Company’s Series A-1 Units with the Investor, as more particularly set forth below and subject to the terms and conditions of th
PURCHASE AGREEMENTPurchase Agreement • April 30th, 2015 • Oncogenex Pharmaceuticals, Inc. • In vitro & in vivo diagnostic substances • New York
PURCHASE AGREEMENT (the “Agreement”), dated as of April 30, 2015, by and between ONCOGENEX PHARMACEUTICALS, INC., a Delaware corporation, (the “Company”), and LINCOLN PARK CAPITAL FUND, LLC, an Illinois limited liability company (the “Investor”).
